Researchers & Healthcare Professionals

TAP Pipeline Chart 17Jun2014 BATAP Pipeline Chart 17Jun2014 AC

Ongoing Studies

Studies Starting Soon

  • None 

    Celator Pharmaceuticals 

    Phase 3, Multicenter, Randomized Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients 60-75 Years of Age with Untreated High Risk Secondary AML

    The primary purpose of this study is to confirm the efficacy of CPX-351 compared to 7 3 (Cytarabine and Daunorubicin) as first line therapy in elderly patients (60-75 yrs) with high risk secondary Acute Myeloid Leukemia. identifier: NCT01696084

    For more information contact:
    Arthur C Louie, MD
    (609) 243-0123

    Kim H Paulsen
    (609) 243-6235

    Visit the Celator Pharmaceuticals website for additional information.


    Acetylon Pharmaceuticals, Inc.

    A Phase 1/2, Open-Label, Multicenter Study of ACY-1215 Administered Orally as Monotherapy and in Combination with Bortezomib and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma 

    Phase 1 (a&b): To evaluate the side effects and determine the best dose or oral ACY-1215 as monotherapy, and also in combination with bortezomib and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma.

    Phase 2a: To determine the objective response rate of oral ACY-1215 in combination with bortezomib and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma. identifier: NCT01323751

    For more information contact:
    Gina Leone
    Acetylon Pharmaceuticals, Inc.
    (617) 638-0475

    Visit the Acetylon Pharmaceuticals website for additional information.


    Curis, Inc.

    Phase I Open Label, Multi-center, Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Orally Administered CUDC-907, a PI3K and HDAC Inhibitor, in Subjects With Refractory or Relapsed Lymphoma or Multiple Myeloma

    The purpose of this phase I, open-label, dose-escalation study of CUDC-907 in patients with refractory or relapsed lymphoma or multiple myeloma is to assess the safety, including the maximum tolerated dose, the pharmacokinetics, and the anti-cancer activity of CUDC-907. CUDC-907 is a multi-targeted agent designed to inhibit phosphoinositide 3-kinase (PI3K) and histone deacetylase (HDAC). identifier: NCT01742988

    For more information contact the recruiting sites:
    Heather Pedigo
    Sarah Cannon Research Institute
    Nashville, TN, 37203
    (615) 329-7432

    Amy Copeland, RN, MSN, CNS
    Memorial Sloan-Kettering Cancer Center
    New York, NY 10065
    (212) 639-6104

    Visit the Curis website for additional information.


    Constellation Pharmaceuticals

    A Phase 1 Study of CPI-0610, a Small Molecule Inhibitor of BET (Bromodomain and Extra-terminal) Proteins, in Patients With Progressive Lymphoma

    The purpose of this study is to investigate the first in human, open-label, sequential dose escalation and expansion study of CPI-0610 in patients with progressive lymphoma. CPI-0610 is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins. identifier: NCT01949883

    For more information contact the recruiting sites:
    Leah Cappadona
    John Theurer Cancer Center 
    Hackensack, NJ, 07601
    (551) 996-5078       
    Principal Investigator: Andre Goy, MD

    Sarah Cannon Research Institute
    Nashville, TN, 37203
    (877) 691-7274       
    Principal Investigator: Ian Flinn, MD, PhD 

    Visit the Constellation Pharmaceuticals website for additional information.  


    University of Florida and The Leukemia & Lymphoma Society

    A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS)

    This study is intended to determine the safety and maximum tolerated dose of a drug, OXi4503 (combretastatin A1 diphosphate, CA1P, OXiGENE), in patients with relapsed and refractory AML and MDS. identifier: NCT01085656

    For more information contact:
    Leslie Pettiford, RN, Study Coordinator
    University of Florida Shands Cancer Center
    (352) 273-6839

    Visit the University of Florida website for additional information. 


    University of Colorado and The Leukemia & Lymphoma Society

    A Phase 2 Study of PF-04449913 for the Treatment of Acute Leukemia Patients With High Risk of Post-Allogeneic Stem Cell Transplantation Relapse

    Disease relapse is the most common cause of death after allogeneic stem cell transplantation for acute leukemia. Patients at high risk for relapse may benefit from a novel, biologically rational therapeutic intervention to prevent this outcome. PF-04449913 is a small molecule inhibitor of the hedgehog (Hh) pathway that inhibits the protein Smoothened (SMO). Aberrant Hh signaling may contribute to the survival and expansion of the leukemia stem cell, and inhibiting the Hh pathway can eliminate these cells. Therefore, targeting Hh may be a logical intervention in the post-transplantation setting for those with high risk of relapse.

    This is an open label, phase 2 study employing PF-04449913 in acute leukemia patients who received allogeneic stem cell transplantation and are at high risk of relapse. Patients will receive consecutive 28-day cycles of PF-04449913 at 100 mg/day, beginning on post-transplantation day 80 /- 10 days, after their routine post-transplant bone marrow biopsy. Treatment will continue for up to one year or until they experience toxicity or disease relapse. identifier: NCT01841333

    For more information contact:
    Nicole Ayodeji
    University of Colorado Cancer Center
    Aurora, Colorado, 80045
    (720) 848-0701 

    Visit the University of Colorado website for additional information.


    Johns Hopkins University and The Leukemia & Lymphoma Society

    Randomized Phase II Study of Autologous Stem Cell Transplantation With Tadalafil and Lenalidomide Maintenance With or Without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma

    This research is being done to find out if altering the immune system by giving Tadalafil and activated marrow-infiltrating lymphocytes (aMILs) can improve outcomes for multiple myeloma patients who receive a standard autologous stem cell transplant. identifier: NCT01858558

    For more information contact:
    Ivan Borrello
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Baltimore, Maryland, 21231
    (410) 955-4967 

    Visit the Johns Hopkins University website for additional information.


    Mayo Clinic and The Leukemia & Lymphoma Society

    A Phase I/II Clinical Trial of Lenalidomide in Combination With AT-101 for the Treatment of Relapsed B-cell Chronic Lymphocytic Leukemia (B-CLL)

    The purpose of this research study is to learn about the maximum amount of lenalidomide along with a fixed dose of AT-101 that may be given safely to individuals with CLL and the types of side-effects that occur with this drug during the Phase I portion. During the Phase II, the purpose is to determine the safety and possible effectiveness against CLL and identify side effects of AT-101 with lenalidomide. identifier: NCT01003769

    For more information contact:
    Mayo Clinic Clinical Trials Referral Office
    Mayo Clinic
    Rochester, Minnesota, 55905
    (507) 538-7623 

    Visit the Mayo Clinic website for additional information.

    last updated on Thursday, July 24, 2014

    Why LLS?

    Your gift will be used to fund vital research and support our patient and community services.

    Questions? Contact us.



    A free resource provided by the National Institutes of Health - access more than 20 million biomedical literature citations.

    Learn More